Related Experiment Video
Updated: May 1, 2026
06:51
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
13.6K
Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition
Stanley R Riddell1, Daniel Sommermeyer, Carolina Berger
1From the Fred Hutchinson Cancer Research Center, Seattle, WA.
Cancer Journal (Sudbury, Mass.)
|March 27, 2014
Summary
Chimeric antigen receptor (CAR) T-cell therapy shows promise for cancer immunotherapy, particularly for B-cell malignancies targeting CD19. This review explores challenges and rationale for using defined T-cell subsets in CAR T-cell therapy.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Engineering
Background:
- Chimeric antigen receptor (CAR) T-cell therapy represents a significant advancement in cancer immunotherapy.
- Current clinical applications primarily focus on targeting CD19 for B-cell malignancies.
Purpose of the Study:
- This review discusses the rationale for and challenges associated with employing genetically modified T cells with defined subset and phenotypic composition in adoptive therapy.
- It highlights the need for greater uniformity in CAR T-cell products.
Main Methods:
- Literature review of current CAR T-cell therapy trials and research.
- Analysis of the implications of T-cell subset selection and composition.
Main Results:
- Clinical trials have not consistently selected defined T-cell subsets before transduction.
- There is a lack of uniformity in the CD4 and CD8 cell composition of current CAR T-cell products.
Conclusions:
- Selecting defined T-cell subsets and ensuring phenotypic uniformity are critical for optimizing CAR T-cell therapy efficacy and safety.
- Further research is needed to overcome the challenges in achieving consistent and defined T-cell product composition for improved cancer treatment outcomes.
